Teva, Takeda deal

Teva granted Takeda exclusive, Japanese rights to develop and commercialize rasagiline, which is approved as Azilect in more than 40 countries for Parkinson's disease (PD). Takeda will be responsible for developing rasagiline for the Japanese market and submitting an NDA for the product in the country. The irreversible selective inhibitor of monoamine oxidase B (MAO-B) has completed Phase I testing in Japan. Takeda declined to disclose details, and Teva could not be reached in time for publication. ...